Adding the investigational drug elraglusib to standard first-line gemcitabine and nab-paclitaxel (GnP) may extend the lives of some patients with metastatic pancreatic ductal adenocarcinoma (PDAC), ...
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. With an overall survival rate of around 13%, it’s also one of the deadliest cancers. One reason for this is that ...
The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Cystic adenocarcinoma (marked in red) of the pancreas (outlined in green). Contrast‑enhanced ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results